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Background: Rates of laboratory testing and diagnostic practices for congenital CMV in the United States are
unknown. We determined rates of CMV testing and diagnostic coding for CMV among insured infants in the United
States using a national healthcare claims database.
Methods: We analyzed medical claims from 2011 Truven Health MarketScan® Commercial databases for infants
who were ≤30 days of age. We used ICD-9-CM codes to identify infants with CMV and CMV-associated conditions.
We computed frequencies of infants with CPT codes for CMV testing.
Results: A total of 368,266 infants met the study criteria. We identified 61 (0.02%) infants with a diagnostic code for
CMV. Among the 368,266 infants, 229 (0.1%) infants had a code for CMV-specific testing, of which 43% had codes
for CMV polymerase chain reaction (PCR) and/or CMV direct florescent antibody (DFA) testing, 44% for CMV
serologic testing alone, and 13% for CMV serology and non-specific PCR and/or culture. Over 80% (187/229) with
CMV testing had a code for ≥1 CMV-associated conditions. Although infrequently coded for, CMV testing was more
common among infants with a code for a condition possibly associated with CMV than infants without these
conditions (0.14% (187/ 136,857) vs. 0.02% (42/231,409)).
Conclusions: The low rates of CMV testing among infants with symptoms suggestive of congenital CMV infection
and the substantial proportion of infants tested with only serologic assays instead of PCR or viral culture suggests
gaps in awareness and knowledge of congenital CMV and its diagnosis among healthcare providers. Although
claims databases presumably do not capture all diagnosed CMV cases or CMV-specific testing, healthcare claims are
a potential source for surveillance and monitoring practices of CMV-specific testing and diagnostic coding for CMV
among infants.
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Cytomegalovirus (CMV) is the most common congenital
viral infection in the United States, affecting approxi-
mately 0.7% of all newborns, of which an estimated 90%
will be asymptomatic at birth [1-4]. It is estimated that
up to 0.2% of U.S. infants have signs and symptoms of
congenital CMV infection at birth, based on retrospect-
ive analyses of infants diagnosed with congenital CMV
[3]. Recognizing congenital CMV disease in the neonatal
period can be challenging since manifestations such as
microcephaly, chorioretinitis, and thrombocytopenia are
not unique to CMV infection [5-7]. Consequently, few
infants with even symptomatic congenital CMV are
likely to receive a diagnosis in the absence of screening.
Because 40-58% of surviving infants with congenital
CMV infections that are symptomatic at birth will de-
velop permanent sequelae [2], diagnosis of congenital
CMV disease in the newborn period is important for
identifying those with neurologic abnormalities who may
benefit from treatment with antivirals as well as those
who will need ongoing management of CMV-related se-
quelae such as hearing and vision loss.
Up to 12% of infants with congenital CMV infection
that are asymptomatic at birth will develop CMV-related
hearing loss later in childhood [2]. Routine newborn
screening for congenital CMV infection is not currently
recommended; rates of laboratory testing for congenital
CMV infection and ascertainment of congenital CMV
disease in the United States are unknown. Congenital
CMV infection is confirmed by detection of CMV DNA
by PCR or CMV by viral culture from urine, saliva, or
blood [8]. In order to distinguish between congenital
and postnatal infection, testing should be conducted
within the first 2–3 weeks after birth [9] as infants may
acquire CMV from infected cervical and vaginal secre-
tions during delivery, breast milk feeding, or blood
transfusions.
The objective of this study was to determine, in the
absence of recommendations for routine screening for
congenital CMV infection or disease, rates of coding for
CMV diagnosis and testing among insured infants less
than one month of age in the United States using a large
national healthcare claims database.
Methods
Data source
We used healthcare claims data from the 2011 Truven
Health MarketScan® Commercial Databases (Truven
Health MarketScan Databases, Truven Health Analytics,
Inc, Ann Arbor, MI) for approximately 50 million em-
ployees and their beneficiaries in the United States [10].
We used outpatient and inpatient claims data from the
2011 MarketScan Commercial Claims and Encounters
databases, including information on demographics,health plan membership, International Classification of
Diseases-9th revision, Clinical Modification (ICD-9-CM)
codes, and Current Procedural Terminology (CPT)
codes. This study of de-identified data was determined
not to require institutional review board review.
Study definitions
Infants were 2011 enrollees ≤30 days of age. Since date
of birth was not available in the MarketScan database,
we used the date of the first claim with an ICD-9-CM
code for live birth or ICD-9-CM V29 (observation and
evaluation of newborns and infants) in 2011 to approxi-
mate the birth date as >90% claims with a newborn code
occurred within 5 days of the first occurrence of the
code.
Cases of congenital CMV were defined as infants ≤30
days of age with an ICD-9-CM code for congenital CMV
infection (771.1) or CMV disease (078.5); we did not in-
clude laboratory confirmation of CMV infection because
laboratory testing results were not available in the
MarketScan database. CMV-associated conditions, iden-
tified by ICD-9-CM codes listed in Additional file 1:
Table S1, were defined as 11 conditions included in pre-
viously published definitions of symptomatic congenital
CMV [5-7] present in the newborn period (within the
first month of birth). We defined “CMV-specific testing”
as a claim with a CPT code for CMV IgG, IgM, direct
florescent antibody testing (DFA), enzyme immunoassay
(EIA) or polymerase chain reaction (PCR) and “non-spe-
cific viral or molecular testing” as a claim with a CPT
code for non-specific viral culture or DNA molecular
diagnostic testing (Additional file 1: Table S1). In order
to characterize practices in laboratory testing for CMV,
we looked at claims for all types of CMV-specific tests
without restricting to laboratory tests used for diagnos-
ing congenital CMV infection. We restricted our ana-
lyses for rates of claims for CMV-specific testing, and
diagnostic coding for CMV and CMV-associated condi-
tions to claims within 30 days of the newborn code.
Hearing loss is also a common symptom of CMV in-
fection [2], although it may not be diagnosed in the new-
born period. To examine diagnostic coding for hearing
loss, we examined claims within the 1st year of the new-
born code. A diagnosis of hearing loss was defined as ≥3
medical encounters with a hearing loss code since the
work-up for a diagnosis for hearing loss in infancy often
requires >2 medical evaluations.
Statistical analysis
To investigate the extent to which CMV testing among
infants is captured by MarketScan data, we determined
rates of CMV-specific testing among infants with
≥1 codes for other routinely recommended laboratory
tests that are typically performed as part of standard
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hypothyroidism, galactosemia, and hemoglobinopathies
(Additional file 1: Table S1).
We performed Pearson Chi Square or Fisher’s exact
test to examine whether the presence of a code for
CMV-specific testing was associated with a code for any
of 11 CMV-associated conditions. The data were ana-
lyzed using SAS 9.2 statistical software (SAS Institute,
Inc, Cary, NC).
Results
Infants with a diagnostic code for congenital CMV
infection or CMV disease
Among the 368,266 infants ≤1 month of age, we identi-
fied 61 (0.02%) infants with a diagnostic code for con-
genital CMV infection or CMV disease. Of these, 63.9%
(39/61) had an ICD-9-CM code for congenital CMV in-
fection only, 27.9% (17/61) had an ICD-9-CM code for
CMV disease only, and 8.2% (5/61) had ICD-9-CM
codes for both congenital CMV infection and CMV dis-
ease. Seven (11.5%) had CMV-specific testing; none had
a code for non-specific viral or molecular testing.
Thirty-seven (61%) had an ICD-9-CM code for ≥1
CMV-associated conditions: 41% (25/61) had 1, and 20%
(12/61) had 2–3 CMV-associated conditions. Low birth
weight, jaundice, and thrombocytopenia were the most
common CMV-associated conditions (Table 1).
Infants with CMV laboratory testing
Among the 368,266 infants, 229 (0.1%) had a code for
CMV-specific testing, of which 7 infants (3.0%) had a
diagnostic code for congenital CMV infection or CMV
disease.
Among the 229 infants with CMV-specific testing, 98
(43%) had a code for CMV virologic testing (CMV PCR
or DFA), 101 (44%) had a code for CMV serologic test-
ing (CMV IgG, IgM, or EIA) alone, and 30 (13%) had a
code for CMV serology and non-specific viral or mo-
lecular testing. Among the 101 with a code for CMV
serologic testing alone, 37 (37%) had IgM testing alone,
16 (16%) had both IgG and IgM testing, 43 (43%) had
IgG testing alone, and 5 (5%) had EIA testing alone.
Most infants with a code for CMV-specific testing (187/
229; 82%) had ≥1 codes for a potentially CMV-
associated condition, while fewer of those with only
non-specific viral or molecular testing (599/1091; 55%)
did (Table 1). The most common CMV-associated con-
ditions among infants with a claim for CMV-specific
testing included low birth weight (61%), jaundice (24%),
and thrombocytopenia (16%); 77% (177/229) of infants
with CMV-specific testing had ≥1 codes for one of these
three conditions. Although CMV-specific testing rates
were statistically significantly higher in infants with hep-
atomegaly, jaundice, low birth weight, microcephaly,other congenital anomalies of nervous system, seizures,
and thrombocytopenia than in infants without these
conditions, rates of testing were low among infants with
these conditions, ranging from 0-11%, with the highest
rate of CMV testing occurring among those with hep-
atomegaly (Table 2). There were 542 (0.15%) infants with
a diagnosis of hearing loss (≥3 visits for hearing loss
within the 1st year); 6 (1.1%) had CMV-specific testing in
the first month of life.
When we restricted the analysis to the 38,344 (10.4%)
infants with ≥1 codes for other laboratory tests, a group
which may have had more complete test claims data,
our findings were similar. The overall rate of CMV-
specific testing in this sub-group was 0.3% (129/38,344)
with rates of testing ranging from 0-38% depending on
presence of CMV-associated conditions, with the highest
rate among those with hepatomegaly (Table 2).
Discussions
This is the first study to examine the frequencies of
diagnostic coding for congenital CMV and CMV labora-
tory testing among infants ≤1 month of age using
healthcare claims data from a large insured population
in the United States. We found that CMV-specific test-
ing is rarely coded for infants and most CMV-specific
testing appears to have been conducted for diagnostic
purposes since 82% of those tested had a claim for at
least one potential manifestation of congenital CMV dis-
ease. We found that 44% of CMV-specific testing
conducted among infants ≤1 month of age appeared to
be limited to serologic assays. Virologic testing is neces-
sary for confirmation of congenital CMV infection be-
cause CMV IgG detected in newborns may reflect
maternal antibody transmission and assays to detect
CMV IgM antibodies lack sensitivity and specificity [7].
Although virologic testing was historically used as the
gold-standard for diagnosing CMV, PCR testing for
CMV is now widely accepted and the preferred method
in some settings. While the low rates of CMV testing
among infants with symptoms suggestive of congenital
CMV infection and the high proportion of infants who
appeared to have been tested only with serologic assays
instead of PCR or viral culture may be explained in part
by incomplete medical claims coding or bundling of ser-
vices, these findings suggests gaps in awareness among
healthcare providers of congenital CMV disease and its
diagnostic evaluation.
We identified 0.02% of infants ≤ 1 month of age as
having congenital CMV infection or CMV disease in a
privately-insured population using healthcare claims
data. That is a small percentage of the true rate of con-
genital CMV infection in the US population. The low
rate of diagnosis of congenital CMV disease that we re-
port likely reflects a combination of the insensivity of
Table 1 Presence of a code for CMV-associated conditionsa among all infants, infants with CMV-specific testing, infants
with non-specific testing, and infants with a diagnostic code for CMV, MarketScan 2011b




Infants with an ICD-9-CM code for
congenital CMV infection
or CMV disease
N=368,266 N=229 N=1,091 N=61
# (%) # (%) # (%) # (%)
Chorioretinitis 13 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Encephalitis 12 (0.0) 0 (0.0) 3 (0.3) 0 (0.0)
Hepatomegaly 45 (0.1) 5 (2.2) 1 (0.1) 0 (0.0)
Jaundice 110,997 (30.1) 54 (23.6) 361 (33.1) 11 (18.0)
Low Birth Weight 33,933 (9.2) 139 (60.7) 266 (24.4) 24 (39.3)
Microcephaly 115 (0.0) 5 (2.2) 7 (0.6) 3 (4.9)
Other Congenital Anomalies of
Nervous System
988 (0.3) 24 (10.5) 28 (2.6) 4 (6.6)
Petechiae 1,650 (0.5) 1 (0.4) 2 (0.2) 1 (1.6)
Seizures 1,057 (0.3) 21 (9.2) 55 (5.0) 4 (6.6)
Splenomegaly 10 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Thrombocytopenia 1,120 (0.3) 36 (15.7) 40 (3.7) 5 (8.2)
Any of the above 11 CMV-associated
conditions
136,857 (37.2) 187 (81.7) 599 (54.9) 37 (60.7)
None of the above 11 CMV-associated
conditions
231,409 (62.8) 42 (18.3) 492 (45.1) 24 (39.3)
aSee Additional file 1: Table S1 for ICD-9-CM and CPT codes used to identify CMV-associated conditions.
bInfants are defined as enrollees ≤ 1 month of age with ≥1 medical claim within 30 days of a newborn code (defined as either a code for live birth, or observation
and evaluation of newborns and infants; codes defined in Additional file 1: Table S1).
cCMV-specific testing includes CMV serologic testing (CMV IgG, CMV IgM, and CMV EIA), CMV DFA, and CMV PCR testing. (See Additional file 1: Table S1 for CPT codes).
dNon-specific testing includes viral culture, molecular diagnostics, or infectious agent detection. (See Additional file 1: Table S1 for CPT codes).
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included in medical records, and the low rate of clinical
diagnosis of congenital CMV which could reflect low
awareness among healthcare providers of congenital
CMV disease as well as the non-specific nature of symp-
toms. Although healthcare claims databases are not sen-
sitive enough to identify all symptomatic congenital
CMV infections in the United States, they may be useful
for surveillance to monitor trends in testing practices
and diagnostic coding for congenital CMV disease in the
absence of national surveillance for congenital CMV in-
fection or disease.
An additional factor that might help account for the
low frequency of diagnoses of congenital CMV in the
present study is the selective nature of the MarketScan
population, which represents individuals with employer-
sponsored health insurance, about 55% of the US popu-
lation in 2011 [11]. People with employer-sponsored
insurance are less likely to be low-income or non-white
than are uninsured or publicly-insured people [12]. Fu-
ture work could examine the frequencies of coding for
CMV diagnosis and CMV testing rates in the US popu-
lation with publicly-financed health insurance.
There are a number of challenges to using claims data
to investigate laboratory testing for congenital CMVinfection. We were only able to identify infants with a
diagnostic code for CMV infection, but were unable to
confirm congenital CMV infection without access to
laboratory test results or medical record review. The
proportion of infants with CMV testing is likely
underestimated as there is no specific billing code for
CMV-specific viral culture. However, even if some of the
claims for non-specific viral or molecular testing actually
represented CMV-specific testing, the rate of CMV test-
ing would still be quite low. It is unclear the extent to
which CMV diagnostic testing was performed but not
billed for with individual test codes; our finding that only
10% of infants had a code for one of the other routinely
performed laboratory tests, suggests that there may be
additional testing occurring that is not detectable be-
cause of bundling of charges. Many of the conditions
associated with congenital CMV disease, such as jaun-
dice, low birth weight, and hearing loss, are non-specific
and have numerous potential underlying etiologies. It is
difficult to definitively determine from medical claims
data whether these conditions were due to congenital
CMV infection but not recognized by providers as being
CMV-related, coded to indicate an evaluation rather
than diagnosis of CMV, or if an alternative etiology was
identified. Some signs of symptomatic congenital CMV
Table 2 CMV-specific testinga by presence or absence of a code for CMV-associated conditions among infants ≤1





Infants with Routine Laboratory Testingd
N=38,344
Total Tested P-value Total Tested P-value
# # (%) # # (%)
Chorioretinitis
No 368,253 229 (0.06) 1.00 38,340 129 (0.34) 1.00
Yes 13 0 (0.00) 4 0 (0.00)
Encephalitis
No 368,254 229 (0.06) 1.00 38,344 129 (0.34) NA
Yes 12 0 (0.00) 0
Hepatomegaly
No 368,221 224 (0.06) <0.01 38,336 126 (0.33) <0.01
Yes 45 5 (11.11) 8 3 (37.50)
Jaundice
No 257,269 175 (0.07) 0.03 24,584 92 (0.37) 0.09
Yes 110,997 54 (0.05) 13,760 37 (0.27)
Low Birth Weight
No 334,333 90 (0.03) <0.01 34,570 46 (0.13) <0.01
Yes 33,933 139 (0.41) 3,774 83 (2.20)
Microcephaly
No 368,151 224 (0.06) <0.01 38,328 127 (0.33) <0.01
Yes 115 5 (4.35) 16 2 (12.50)
Other Congenital Anomalies
of Nervous System
No 367,278 205 (0.06) <0.01 38,206 116 (0.30) <0.01
Yes 988 24 (2.43) 138 13 (9.42)
Petechiae
No 366,616 228 (0.06) 1.00 38,134 129 (0.34) 1.00
Yes 1,650 1 (0.06) 210 0 (0.00)
Seizures
No 367,209 208 (0.06) <0.01 38,210 116 (0.30) <0.01
Yes 1,057 21 (1.99) 134 13 (9.70)
Splenomegaly
No 368,256 229 (0.06) 1.00 38,343 129 (0.34) 1.00
Yes 10 0 (0.00) 1 0 (0.00)
Thrombocytopenia
No 367,146 193 (0.05) <0.01 38,156 108 (0.28) <0.01
Yes 1,120 36 (3.21) 188 21 (11.17)
Any of the above 11
CMV-associated conditions
No 231,409 42 (0.02) <0.01 21,968 19 (0.09) <0.01
Yes 136,857 187 (0.14) 16,376 110 (0.67)
a CMV-specific testing includes CMV serologic testing (CMV IgG, CMV IgM, and CMV EIA), CMV DFA, and CMV PCR testing. (See Additional file 1: Table S1 for CPT codes).
bInfants are defined as enrollees ≤ 1 month of age with ≥1 medical claim within 30 days of a newborn code (defined as either a code for live birth, or observation
and evaluation of newborns and infants; codes defined in Additional file 1: Table S1).
cSee Additional file 1: Table S1 for ICD-9-CM and CPT codes used to identify CMV-associated conditions.
d Infants with ≥1 codes for other routinely recommended laboratory tests that are typically performed on infants as part of standard care. These tests included
phenylketonuria, hypothyroidism, galactosemia, and hemoglobinopathies.
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unlikely to be coded in claims data, even if recognized
and recorded in the medical record. Finally, we were un-
able to validate the sensitivity and specificity of codes for
CMV testing and diagnosis using medical claims. In the
future, it would be useful to conduct a validation study
of coding to enhance the interpretability of claims data
for CMV testing and diagnostic coding.
Conclusions
This study provides data on testing practices for con-
genital CMV infection among a sample of privately-
insured infants in the United States. The substantial pro-
portion of infants tested with only serologic assays in-
stead of PCR or viral culture suggests gaps in knowledge
of laboratory confirmation of CMV infection. Further in-
vestigation of the low prevalence of diagnosed symptom-
atic congenital CMV disease detected in this population
merits further research to understand the true burden
and spectrum of congenital CMV disease in this popula-
tion, the extent to which symptomatic congenital CMV
disease may go undiagnosed, and the validity of medical
claims data for identifying this condition whether claims
data could be an adequate source for surveillance to
monitor trends in CMV testing and diagnostic coding in
the United States. As the indications for and benefits of
antiviral treatment for congenital CMV disease in early
infancy are refined, increasing awareness and prompt as-
certainment of congenital CMV is important to ensure
identification of all infants who might benefit from early
treatment.
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